Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (3,405,000)	$ (1,921,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	699,000	615,000
Common stock issued for services	46,000	97,000
Credit loss expense	0	37,000
Amortization of debt discount	62,000	28,000
Amortization of right-of-use operating lease assets	49,000	27,000
Amortization of right-of-use finance lease asset	28,000	16,000
Operating lease liabilities	(47,000)	(25,000)
Finance lease liability	(24,000)	(21,000)
Gain on investment in South Korean joint venture	0	(2,000)
Depreciation expense	34,000	42,000
Changes in assets and liabilities:
Accounts receivable	(115,000)	(1,077,000)
Inventories	18,000	(39,000)
Prepaid expenses and other assets	3,000	14,000
Deposits	(1,000)	0
Contract liabilities	39,000	0
Net cash used in operating activities	(2,917,000)	(1,830,000)
Cash flows from investing activities
Equipment purchases	(32,000)	0
Net cash used in investing activities	(32,000)	0
Cash flows from financing activities
Proceeds from sale of common stock, net of offering costs	256,000	(15,000)
Common stock issued for financing fee	85,000	0
Repayment of debt obligations	(8,000)	(4,000)
Proceeds from Clyra Medical debt obligations	2,395,000	590,000
Net cash provided by financing activities	3,190,000	866,000
Net effect of foreign currency translation	(2,000)	(20,000)
Net change in cash	239,000	(984,000)
Cash and cash equivalents at beginning of period	3,883,000	3,548,000
Cash and cash equivalents at end of period	4,122,000	2,564,000
Supplemental disclosures of cash flow information
Interest	126,000	37,000
Income taxes	0	0
Short-term lease payments not included in lease liabilities	13,000	12,000
Non-cash investing and financing activities
Allocation of noncontrolling interest	(641,000)	(522,000)
Fair value of Clyra Medical warrants issued as debt discount	232,000	69,000
Clyra Medical dividend Series A Preferred stock	86,000	86,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock, net of offering costs	0	295,000
BioLargo Energy Technologies, Inc (BETI) [Member]
Cash flows from financing activities
Proceeds from BETI unit offering	462,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	(135,000)	290,000
Accounts payable and accrued expenses	(135,000)	290,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	(168,000)	89,000
Accounts payable and accrued expenses	$ (168,000)	$ 89,000

BIOLARGO, INC. 10-Q